On (b)(6) 2018, abaxis received a call from the customer lab stating that the device yielded an unexpected high potassium result compared to a draw on a different device and lot.The lab treated the patient to lower potassium levels then redrew a sample approximately 45 minutes later and tested the sample on a different piccolo analyzer and lot.The customer then set the test tube to the lab for analyzing.The lab ran controls on a different lot on 07-march-2018.The control samples were sent to test the lot in question.The lab ran controls on the lot on 09-march-2018 and both levels were within range.Abaxis technical support provided in-service training based on the potassium troubleshooting chart previously sent by technical support.The abaxis representative reinforced the protocol to rerun an abnormal result before treating a patient.The lab has not experienced any more unexpected high potassium results since and the device remains at the customer site.No further actions were required.This mdr is being submitted as a result of a three (3) year retrospective review of closed complaints abaxis performed as part of its commitment to correct the fda-483 observations received on august 22, 2019.
|